Blue Crest Capital Management LTD Tyme Technologies, Inc. Transaction History

Blue Crest Capital Management LTD

  • $1.62 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2018

May 15, 2018
SELL
$2.12 - $7.0 $82,060 - $270,956
-38,708 Closed
0 $0
Q4 2017

Feb 14, 2018
BUY
$3.25 - $7.3 $125,801 - $282,568
38,708
38,708 $247,000

About TYME TECHNOLOGIES, INC.

TYME Quotes by TradingView
  • Ticker TYME
  • Exchange NASDAQ
  • Shares Outstandng 172,207,008
  • Description
  • Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also devel...
More about TYME
Track This Portfolio

Track Blue Crest Capital Management LTD Portfolio

Follow Blue Crest Capital Management LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Blue Crest Capital Management LTD, based on Form 13F filings with the SEC.

News

Stay updated on Blue Crest Capital Management LTD with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email